AstraZeneca is to pay $575m to acquire full rights to Takeda's Daxas (roflumilast), along with other respiratory assets. The move is the latest in a series of bolt-on acquisitions by the UK firm to bulk up its position in respiratory, one of its core therapeutic franchises along with oncology and cardiovascular/metabolic.
AstraZeneca is to pay $575m to acquire full rights to Takeda's Daxas (roflumilast), along with other respiratory assets. The move is the latest in a series of bolt-on acquisitions by the UK firm to bulk up its position in respiratory, one of its core therapeutic franchises along with oncology and cardiovascular/metabolic.
Daxas is an oral PDE4 inhibitor used as an add-on to bronchodilation treatments to reduce exacerbations in patients with severe chronic obstructive pulmonary disease (COPD)
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
